Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iLLUMINATE: Ibrutinib + Obinutuzumab vs Chlorambucil + Obinutuzumab in TN CLL/SLL
NCT02264574Phase 3Completed
- Sponsor
- Pharmacyclics
- Start
- Oct 2014
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of ibrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Pharmacyclics. Started Oct 2014; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02264574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264574.